Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Unknown 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

sotorasib 1niraparib 1Panitumumab 1Immune Checkpoint Inhibitors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Efficacy × Clear all
NCT06237205 2024-02-01

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Korea University Anam Hospital

Phase 2 Not yet recruiting
33 enrolled

Efficacy

NCT05993455 2023-08-15

A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab

Korea University Anam Hospital

Phase 2 Unknown
24 enrolled

Efficacy

NCT05427305 2022-06-22

TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer

BioDlink Biopharm Co., Ltd.

Phase 3 Completed
549 enrolled

Efficacy

NCT05325684 2022-04-13

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

The Affiliated Hospital of Qingdao University

Phase 1/2 Unknown
30 enrolled

Efficacy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡